Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Multiple Sclerosis Health Center

Font Size

New Oral MS Drugs May Be on the Horizon

Studies Show Cladribine and Fingolimod Are Effective Treatments for Multiple Sclerosis
WebMD Health News
Reviewed by Louise Chang, MD

Jan. 20, 2010 -- Two new drugs for multiple sclerosis, both taken orally, reduce the rates of relapses in multiple sclerosis patients -- sometimes keeping 80% or more of patients relapse-free during the study period -- according to new research. The new drugs, if approved, promise an end to injections for some patients.

Results of three studies looking at cladribine and fingolimod for the form of MS known as relapsing-remitting are published online in the New England Journal of Medicine. In an accompanying editorial, a doctor suggests the new drugs could provide a ''new horizon'' for patients and a welcome increase in treatment options.

"These results are big in that first of all, both these therapies look to be very effective, appear to be well tolerated, and they have a novel mechanism of action," says Jeffrey A. Cohen, MD, director of experimental therapeutics at the Mellen Center for Multiple Sclerosis at the Cleveland Clinic and lead researcher of one of the studies.

These two new options may be just the beginning, Cohen tells WebMD. "I think they are harbingers of other medicines on the horizon."

About 400,000 Americans have MS, a chronic, often disabling disease, according to the National Multiple Sclerosis Society. The body turns on itself, attacking myelin, the fatty substance protecting nerve fibers in the central nervous system, leading to damaged nerve fibers and hindering nerve impulses from traveling to and from the brain and spinal cord. That, in turn, produces symptoms such as numbness, limb weakness, and blurred vision. About 85% of MS patients are initially diagnosed with the form of MS known as relapsing-remitting, in which flare-ups are followed by remissions.

The two new drugs would be the first treatment options that don't involve injections or infusions.

Fingolimod for MS

Cohen's team compared fingolimod in two doses -- 1.25 milligrams or 0.5 milligrams -- with an established treatment for MS, intramuscular injection of interferon beta-1a (Avonex) at a dose of 30 micrograms per week.

When the researchers looked at the relapse rate after 12 months in 1,153 patients randomly assigned to one of the three treatment groups, they found that the relapse rate was lower in both groups getting fingolimod.

1 | 2 | 3

Today on WebMD

nerve damage
Learn how this disease affects the nervous system.
woman applying lotion
Ideas on how to boost your mood and self-esteem.
woman pondering
Get personalized treatment options.
man with hand over eye
Be on the lookout for these symptoms.
brain scan
worried woman
neural fiber
white blood cells
sunlight in hands
marijuana plant
muscle spasm